Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 2; Phase 1

Conditions: Obesity

Treatments: Drug: BMS-830216; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00909766

MB123-002

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability and effect on body weight and other obesity-related factors of different doses of BMS-830216, compared to placebo. The study will also determine the amount of BMS-830216 in the blood.

Enrollment: 113 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Obese subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Body Mass Index (BMI) of 30 to 40 kg/m², inclusive
• Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men, ages 18 to 55, inclusive

Exclusion criteria

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population
• Female of childbearing potential
• Sexually active fertile male not using effective birth control method (for example, condom) if your partners are females of childbearing potential
• Abnormal blood work results (for example, triglyceride ≥ 400 mg/dL, glucose ≥126 mg/dL and total cholesterol ≥ 300 mg/dL)
• High blood pressure (≥160/95 mm Hg)
• Major surgical procedure within 4 weeks prior to randomization
• Chronic infections (e.g., HIV [human immunodeficiency virus] or Hepatitis C)
• Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease, or a previous surgery for weight loss
• History of gastrointestinal disease within the past 3 months
• History of Type I or Type II diabetes in the past 12 months
• A lifetime history of a suicide attempt or history of any suicidal behavior in the past month
• Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator
• Used grapefruit or grapefruit juice within 1 week prior to randomization
• Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization
• Unable to tolerate oral and/or intravenous (IV) medications
• Unable to tolerate the puncturing of veins for drawing of blood
• Prior exposure to BMS-830216
• History of prior weight loss (for example, gastric bypass or gastric banding) or gastrointestinal surgery that could impact the absorption of study drug
• History of a Major Depressive Disorder within the past 2 years
• Known allergy or hypersensitivity to any component of the study medication
• History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)
• Used any oral, injectable or implantable hormonal contraceptive agents (for example, birth control pills, Depo-Provera, or NuvaRing) within 3 months prior to randomization
• Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization
• Used any prescription drugs, over the counter medications and herbal preparations within 1 week prior to randomization
• Taken St. John's Wort within 1 week prior to randomization
• Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to randomization

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

113 participants in 8 patient groups, including a placebo group

Panel A

Active Comparator group

Treatment:

Drug: Placebo

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Panel B

Active Comparator group

Treatment:

Drug: Placebo

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Panel C

Active Comparator group

Treatment:

Drug: Placebo

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Panel D

Active Comparator group

Treatment:

Drug: Placebo

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Panel E

Active Comparator group

Treatment:

Drug: Placebo

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Panel F

Active Comparator group

Description:

Low Dose

Treatment:

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Panel G

Active Comparator group

Description:

High Dose

Treatment:

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Drug: BMS-830216

Panel H

Placebo Comparator group

Treatment:

Drug: Placebo